Drugs that contain Norepinephrine Bitartrate
1. List of Norepinephrine Bitartrate In 0.9% Sodium Chloride drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11413259 | NEVAKAR INJECTABLES | Norepinephrine compositions and methods therefor |
Jan, 2038
(14 years from now) | |
| US10420735 | NEVAKAR INJECTABLES | Norepinephrine compositions and methods therefor |
Jan, 2038
(14 years from now) | |
| US10226436 | NEVAKAR INJECTABLES | Norepinephrine compositions and methods therefor |
Jan, 2038
(14 years from now) | |
| US10159657 | NEVAKAR INJECTABLES | Norepinephrine compositions and methods therefor |
Jan, 2038
(14 years from now) | |
| US10568850 | NEVAKAR INJECTABLES | Norepinephrine compositions and methods therefor |
Jan, 2038
(14 years from now) | |
Market Authorisation Date: 06 October, 2022
Treatment: Indicated to raise blood pressure in adult patients with severe, acute hypotension
Dosage: SOLUTION;INTRAVENOUS
More Information on Dosage
NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE family patents
11
United States
1
Canada
2. List of Norepinephrine Bitartrate In 0.9% Sodium Chloride drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10888534 | INFORLIFE | Storage stable ready-to-use norepinephrine aqueous solutions in flexible plastic bags |
Apr, 2039
(16 years from now) | |
Market Authorisation Date: 15 September, 2022
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
More Information on Dosage
NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE family patents
1
IB
1
United States
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic